Related Experiment Video
Updated: May 28, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Advances in Vaccine-Based Therapies for Pancreatic Cancer
Matthew T McMillan1,2, Kevin C Soares3,4
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with a 5-year survival rate that has improved only marginally over the past 30 years, despite numerous clinical trials. PDAC poses several unique challenges, including early metastatic spread and a predilection for liver metastasis. It is also highly resistant to anti-tumor immunity and immunotherapy due to its dense and immunosuppressive tumor microenvironment, low immunogenicity, and systemic immune suppression. PDAC has a low mutational burden, defective antigen presentation, and immune checkpoint molecule upregulation, which reduce immune recognition. Together, these factors leave PDAC as an "immune cold" tumor with minimal cytotoxic T-cell activity. Novel therapeutic approaches are urgently needed to reinvigorate anti-tumor immunity. Recent advances, such as adjuvant personalized mRNA neoantigen vaccines and mutant-KRAS targeted vaccines, have demonstrated sustained vaccine-induced T cell responses that are associated with improved recurrence-free survival in surgically resected PDAC. Combining different vaccine approaches with optimal sequencing of chemotherapy, surgery, radiotherapy, and other immunotherapies may further enhance outcomes. PDAC vaccines represent a promising strategy for overcoming PDAC's resistance to conventional therapies, with ongoing trials exploring their potential to improve long-term survival.
Insights
Pancreatic cancer (PDAC) is a lethal disease with poor survival rates. Novel cancer vaccines targeting neoantigens and KRAS mutations show promise in invigorating anti-tumor immunity and improving outcomes for PDAC patients.
Area of Science:
- Oncology
- Immunology
- Cancer Vaccines
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with dismal 5-year survival rates.
- PDAC is characterized by early metastasis, liver tropism, and resistance to immunotherapy due to an immunosuppressive tumor microenvironment and low immunogenicity.
- Factors contributing to immune resistance include low mutational burden, defective antigen presentation, and upregulated immune checkpoints, classifying PDAC as an "immune cold" tumor.
Purpose of the Study:
- To explore novel therapeutic strategies to overcome PDAC's resistance to conventional treatments and reinvigorate anti-tumor immunity.
- To evaluate the potential of personalized mRNA neoantigen vaccines and mutant-KRAS targeted vaccines in treating PDAC.
- To assess the impact of combining vaccine approaches with standard therapies like chemotherapy, surgery, and radiotherapy.
Main Methods:
- Investigated recent advances in cancer vaccine development for PDAC.
- Reviewed clinical trial data on adjuvant personalized mRNA neoantigen vaccines and mutant-KRAS targeted vaccines.
- Examined the role of the tumor microenvironment and immune evasion mechanisms in PDAC treatment resistance.
Main Results:
- Personalized mRNA neoantigen vaccines and mutant-KRAS targeted vaccines have demonstrated sustained T cell responses in PDAC.
- These vaccine-induced T cell responses are associated with improved recurrence-free survival in surgically resected PDAC.
- Combination strategies involving vaccines and standard therapies show potential for enhanced treatment outcomes.
Conclusions:
- PDAC vaccines represent a promising therapeutic strategy to overcome treatment resistance and improve long-term survival.
- Ongoing clinical trials are exploring the efficacy of PDAC vaccines in various treatment settings.
- Further research into combination therapies and optimal sequencing is crucial for maximizing the benefits of PDAC vaccines.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...